Novel mutations of integrin αIIb and β3 genes in Turkish children with Glanzmann's thrombasthenia

被引:9
|
作者
Tokgoz, Huseyin [1 ]
Ozkan, Didem Torun [2 ]
Caliskan, Umran [1 ]
Akar, Nejat [3 ]
机构
[1] Necmettin Erbakan Univ, Meram Fac Med, Dept Pediat Hematol, TR-42080 Meram, Konya, Turkey
[2] Okan Univ, Fac Med, Dept Med Biol, Istanbul, Turkey
[3] TOBB Econ & Technol Hosp, Dept Pediat, Ankara, Turkey
关键词
Glanzmann thrombasthenia; mutation analysis; polymorphism; FIBRINOGEN; IIIA;
D O I
10.3109/09537104.2014.998994
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Glanzmann's thrombasthenia (GT) is an inherited disorder of platelet aggregation, characterized by qualitative and quantitative defect on platelet alpha IIb beta 3 integrin (GpIIb/IIIa), resulting in lifelong bleeding tendency due to defective platelet plug formation. The alpha IIb gene (ITGA2B) and beta 3 gene (ITGB3) are closely located at chromosome 17q21.31-32. ITGA2B consist of 30 exons and encoding alpha chain, whereas ITGB3 has 15 exons and encoding beta chain. Until now, according to the Human Gene Mutation Database (HGMD), 138 mutations at ITGA2B gene and 101 mutations at ITGB3 gene have been identified. We aimed to determine whether there was any mutation in the ITGA2B and ITGB3 genes, and a correlation between clinical phenotype and genotype in Turkish GT patients. We examined 20 patients with GT followed at the Department of Pediatric Hematology, Meram Faculty of Medicine, for Clinical and Laboratory Findings and Molecular Genetic Analysis. Peripheral blood was collected from patients, and a written informed consent for genetic analysis was obtained from parents. DNA was isolated from by proteinase K and phenol/chloroform extraction. ITGA2B and ITGB3 genes were screened by polymerase chain reaction. There were 12 females and 8 males with a median age of 15.25 years. Major clinical presentations of these patients were mucocutaneous bleedings. The most common bleeding type was epistaxis (85%). Life-threatening bleedings were seen in five patients. Seven (35%) patients showed various mutations in the ITGA2B or ITGB3 genes. We detected four novel mutations in three different regions and two mutations defined previously within the ITGA2B gene. These changes are at exon 4; c.570 T4G alteration, at exon 13 c.1277 T4A, c. 1291 T4G alterations, at exon 19 c.1921A4G alterations. And from the start point of exon 14, behind 107 bases, we detected a heterozygous alteration at Thymine to Guanine. According to PolyPhen Database Program and NCBI Multiple Alignment Tool Database, four transitions are conserved at evolutionary process, so we can say that these transitions are novel mutations. c. 468T4G alteration at exon 4 and c. 1378 T4A alteration at exon 13 were reported to HGMD previously. Screening the exons of the ITGB3 gene from the same patient groups, we reported a novel missense mutation at exon 5, at nucleotide 680. No correlation was found between clinical phenotype and genotype. These mutations were described for the first time in Turkish population, and all novel mutations are not defined previously. Furthermore, collaborative studies are needed for the population point of view.
引用
收藏
页码:779 / 782
页数:4
相关论文
共 50 条
  • [41] Glanzmann Thrombasthenia in Pakistani Patients: Identification of 7 Novel Pathogenic Variants in the Fibrinogen Receptor αIIbβ3
    Siddiqi, Muhammad Younus Jamal
    Boeckelmann, Doris
    Naz, Arshi
    Imran, Ayisha
    Ahmed, Shariq
    Najmuddin, Akbar
    Zieger, Barbara
    CELLS, 2023, 12 (02)
  • [42] Modulation of clinical phenotype of Glanzmann's thrombasthenia by thrombogenic mutations
    Kannan, Meganathan
    Yadav, Birendra Kumar
    Ahmad, Firdos
    Biswas, Arijit
    Saxena, Renu
    CLINICA CHIMICA ACTA, 2009, 403 (1-2) : 156 - 158
  • [43] Detection and Analysis of Gene Mutations in Patients with Glanzmann's Thrombasthenia
    Sun, Boyang
    Zhang, Donglei
    Li, Huiyuan
    Dou, Xueqing
    Yang, Renchi
    BLOOD, 2019, 134
  • [44] Aberrant mRNA processing in compound heterozygote with glycoprotein IIb gene mutations causing Glanzmann thrombasthenia
    Fujita, J.
    Murata, M.
    Kajiura, Y.
    Takagi, A.
    Murate, T.
    Matsushita, T.
    Kunishima, S.
    Kojima, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 403 - 403
  • [45] Treatment and Outcomes for Epistaxis in Children with Glanzmann's Thrombasthenia
    Rosas, R. Raul
    Kurth, Margaret Heisel
    Sidman, James
    LARYNGOSCOPE, 2010, 120 (12): : 2374 - 2377
  • [46] Identification of genotype of Glanzmann Thrombasthenia in Saudi Arabia with report of four novel mutations implicated in classical genes
    Owaidah, Tarek
    Abouelhoda, Mohamed
    Monies, Dorota
    Altassan, Nada
    Khojah, Osama
    Alzahrani, Hazzaa
    Saleh, Mahasen
    Alnounou, Randa
    Alkhail, Hala Aba
    Albanyan, Abdulmajeed
    HAEMOPHILIA, 2016, 22 : 123 - 123
  • [47] Immunization against platelet glycoprotein IIb-IIIa in Glanzmann's thrombasthenia
    Taaning, E
    Knudsen, FU
    Thorsen, S
    Jonsson, V
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1997, 58 (05) : 360 - 361
  • [48] Mutation screening in Glanzmann thrombasthenia: identification of four novel mutations in the ITGA2B and ITGB3 genes
    Theophilus, B. D. M.
    Guilliatt, A. M.
    Baugh, L. M.
    Motwani, J.
    Williams, M. D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 77 - 77
  • [49] Glanzmann thrombasthenia (GT) mutations within the second and third calcium-binding domains of αIIb affect biogenesis of the αIIbβ3 receptor.
    Mitchell, B
    Li, JH
    Michelson, AD
    Bussel, J
    Coller, BS
    French, DL
    BLOOD, 2000, 96 (11) : 816A - 816A
  • [50] First description of an IgM monoclonal antibody causing IIb3 integrin activation and acquired Glanzmann thrombasthenia associated with macrothrombocytopenia
    Pillois, Xavier
    Guy, Alexandre
    Choquet, Emeline
    James, Chloe
    Tuffigo, Marie
    Viallard, Jean-Francois
    Garcia, Cedric
    Bordet, Jean-claude
    Jandrot-Perrus, Martine
    Payrastre, Bernard
    Fiore, Mathieu
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2019, 17 (05) : 795 - 802